Cellectis falls as Citizens downgrades on pivot to genetic medicines

Summary

Cellectis stock declined following a downgrade by Citizens analyst, attributed to the company's pivot toward genetic medicines. The analyst's rating change reflects concerns about the strategic direction shift.